Abstract
11096 Background: Angiogenic cytokines influence tumor growth in mRCC patients (pts) and are modulated by diurnal fluctuations. The timing of antiangiogenic tyrosine kinase inhibitor (TKIs) administration may impact efficacy, toxicity and biomarker expression. Methods: 34 mRCC pts, randomized to receive sunitinib at 8 AM or 8 PM on a 28 days (d) on/14 d off schedule, had blood sampling before and during Rx on the first cycle for potential biomarkers including: sunitinib and metabolite blood levels, 18 circulating angiogenic factors (CAFs) and 4 circulating angiogenic cell types including circulating endothelial cells (CECs). Results: Spearman analysis of the 24 biomarkers obtained on d 14 showed significantly better correlations with OS and PFS in PM-treated pts. Three CAFs in PM-treated pts significantly correlated with both OS and PFS. These included Leptin (r = 0.7182, p = 0.0128 and r = 0.8364, p = 0.0022, respectively), IL-8 (r = -0.635, p = 0.0485 and r = -0.5735, p = 0.031, respectively) and PDGF-β...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
